---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-019652"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2023-05-31T23:59:59+00:00"
generated_at: "2026-06-14T10:30:16.314865+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BriaCell to spin out pre-clinical assets into BriaPro; shareholders get 1 SpinCo share per each held

## Summary
- SpinCo to acquire Bria-TILsRx™ and PKCδ inhibitors from BriaCell.
- Each BriaCell shareholder receives 1 SpinCo share and 1 new BriaCell share; warrants adjusted similarly.
- Shareholders will own 33.33% of SpinCo; BriaCell retains 66.67%.
- Special shareholder meeting scheduled for July 2023; closing targeted by August 2023.
- Conditions: shareholder vote, court orders, TSX and Nasdaq approvals; board unanimously supports.

## SEC filing metadata
- accession: 0001493152-23-019652
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2023-05-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315223019652/0001493152-23-019652-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315223019652/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-019652
- JSON: https://secwatch.observer/filing/0001493152-23-019652.json
- Plain text: https://secwatch.observer/filing/0001493152-23-019652.txt

## Key facts
- Material Agreements
  BriaCell Therapeutics Corp. entered into Arrangement Agreement with BriaPro Therapeutics Corp. valued at spin-out of pre-clinical pipeline assets in exchange for SpinCo common shares; SpinCo Shares represe (effective 2023-05-24).
  - Action: entry
  - Agreement: merger
  - Counterparty: BriaPro Therapeutics Corp.
  - Value: spin-out of pre-clinical pipeline assets in exchange for SpinCo common shares; SpinCo Shares represe
  - Effective: 2023-05-24
  source text: On May 24, 2023, BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) entered into an Arrangement Agreement (the “Arrangement Agreement”) with BriaPro Therapeutics Corp., a British Columbia corporation and wholly-owned subsidiary of the Company (“SpinCo”), pursuant to which the Company will spin out certain of its pre-clinical pipeline assets , including Bria-TILsRxTM and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer (collectively, the “SpinCo Assets”), to SpinCo by way of a court-approved statutory plan of arrangement under Section 288 of the Business Corporations Act (British Columbia) (the “Arrangement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1610820/000149315223019652/0001493152-23-019652-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.